Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2025
Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy
Fazili A, Jazayeri S, Rose K, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson M, Grass G, Xu H, Spiess P, Gilbert S, Sexton W, Zemp L, Pessoa R, Poch M, Lerner S, Li R. Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy. BJU International 2025 PMID: 40932312, DOI: 10.1111/bju.16895.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerCisplatin-ineligible patientsEvent-free survivalCIS patientsOncological outcomesOverall survivalRadical cystectomyBladder cancerCis groupRetrospective comparisonMedian event-free survivalNon-cancer-related deathsAlternative chemotherapy regimensImmediate radical cystectomyMedian overall survivalKaplan-Meier methodLog-rank testTertiary care centreStandard-of-careLong-term survivalMulti-institutional dataCisplatin-eligibleRecurrence-freeChemotherapy regimensRandomised controlled trialsEnd Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
Necchi A, Galsky M, Dizman N, Aggen D, Agarwal N, Al-Ahmadie H, Apolo A, Ballas L, Bangs R, Black P, Brausi M, Brembilla G, Cheng L, Chiti A, Cimadamore A, Colecchia M, Daneshmand S, Di Stasi S, Efstathiou J, Filicevas A, Geynisman D, Grivas P, Gupta S, Iasonos A, James N, Lerner S, Loriot Y, Makaroff L, Maluf F, Moschini M, Ostrovnaya I, Pal S, Plimack E, Prakash G, Psutka S, Rosenberg J, Sadeghi S, Schmidt B, Schwartz L, Sonpavde G, St Laurent M, Ye D, Spiess P, Kamat A. End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. Journal Of Clinical Oncology 2025, jco2501608. PMID: 40934451, PMCID: PMC12431632, DOI: 10.1200/jco-25-01608.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerInternational Bladder Cancer GroupClinical complete responseEvent-free survivalEvolving treatment landscapeBladder cancerDefinition of clinical complete responseConsensus definitionBladder-sparing treatmentCoprimary end pointsHigh-grade malignancyBladder cancer groupClinically meaningful benefitOrgan preservation strategiesEarly-phase studiesMultidisciplinary consensus panelIntention-to-treat approachBladder preservationSurgical consolidationComplete responseGenitourinary tumorsMetastatic diseaseUrine cytologyPerioperative strategiesPerioperative trialsLow-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies
Wen L, Miyagi H, Spiess P, Yu A, Mendelsohn C, Tan W, Psutka S, Lerner S, Cheng L, Dyrskjøt L, Meeks J, Shariat S, Gontero P, Pradere B, Steinberg G, Kamat A, Li R. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nature Reviews Urology 2025, 1-16. PMID: 40931081, DOI: 10.1038/s41585-025-01072-0.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerTreatment strategiesNovel treatment strategiesValidation of novel biomarkersFollow-up monitoringSurveillance cystoscopyFavorable prognosisOffice cystoscopyTargeted therapyImmunomodulatory agentsTreatment optionsEmergency therapyDisease behaviorDrug delivery systemsMolecular landscapeTherapyTreatment burdenStage progressionNovel biomarkersPatientsPatient outcomesDisease biologyHealth care costsProteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer
Holt M, Dou Y, Young M, Saltzman A, Anurag M, Lei J, Jain A, Leng M, Kim B, Dobrolecki L, Faucher S, Savage S, Wang C, Shi Z, Villanueva H, Kremers K, Drinnon K, Castro P, Ittmann M, Khatani M, Kim S, Ellis M, Zhang B, Malovannaya A, Lerner S. Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Reports Medicine 2025, 6: 102255. PMID: 40749681, PMCID: PMC12432383, DOI: 10.1016/j.xcrm.2025.102255.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerIsoform-level analysisBladder cancerMulti-omics clusteringBenefit of combination therapyFamily proteinsPhosphoproteomic dataBiomarkers of chemosensitivityProteogenomic characterizationJAK/STAT pathwayProtein abundanceAssociated with chemoresistanceWnt signalingPD-L1ProteinCombination therapyChemoresistance mechanismsMolecular subtypesChemotherapy sensitivityChemoresistanceTherapeutic opportunitiesATAD1SubtypesGenomeCancerAndrogen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocksCombined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).
Bsteh D, Buckley J, Mitchell S, Ostrow D, Parmentier J, Jahan S, Sadis S, Smith J, NI J, Peng X, McConkey D, Dorff T, Lerner S, Aparicio A, Chapin B, Duddalwar V, Triche T, Goldkorn A. Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17111.Peer-Reviewed Original ResearchProspective phase 3 trialsSingle nucleotide variantsCopy number variantsPhase 3 trialProstate cancerTime pointsProstate cancer-relevant genesCirculating tumor cell DNALiquid biopsy componentsMetastatic prostate cancerMultiple time pointsIon Reporter softwareRecurrent copy number variantsTumor cell DNACell-free DNASingle tube of bloodCancer-relevant genesThermo FisherTubes of bloodPrimary tumorSystemic therapyDefinitive treatmentCtcDNAIndeterminate significancePreservation tubesTRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, Chi K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps5129.Peer-Reviewed Original ResearchMetastatic castration sensitive prostate cancerAndrogen receptor pathway inhibitorsAndrogen deprivation therapyPSA responseOverall survivalDisease volumePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyReceipt of androgen deprivation therapyResponse to androgen deprivation therapyMonths of androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalMonths median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPrimary prostate cancer tissuesNational Clinical Trials NetworkPhase III clinical trialsUrine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
St-Laurent M, Singh P, McConkey D, Lucia M, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzarella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology 2025 PMID: 40404526, DOI: 10.1016/j.eururo.2025.03.023.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerUrine tumor DNAEvent-free survivalTumor DNABladder cancerBCG-unresponsive NMIBCPatients treated with atezolizumabRisk of treatment failureClinical evidence of diseaseRisk of recurrenceEvidence of diseaseSystemic immunotherapyTreatment failureTherapeutic decisionsClinical evidencePatientsUrine samplesAtezolizumabBaselineCancerUrineTreatmentRiskImmunotherapySWOGA festschrift in honor of Ian M. Thompson Jr., MD
Svatek R, Ankerst D, D' Amico A, Flaig T, Ford L, Goldkorn A, Hernandez J, Kumar A, Leach R, Lerner S, Liss M, McConkey D, Minasian L, Morilak D, Mueller E, Parekh D, Platz E, Sudarshan S, Unger J. A festschrift in honor of Ian M. Thompson Jr., MD. Urologic Oncology Seminars And Original Investigations 2025, 43: 423-435. PMID: 40447392, DOI: 10.1016/j.urolonc.2024.10.030.Peer-Reviewed Original ResearchIP24-34 CISPLATIN INELIGIBLE PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER DEMONSTRATE POOR LONG-TERM SURVIVAL FOLLOWING IMMEDIATE RADICAL CYSTECTOMY: A MULTI-INSTITUTIONAL ANALYSIS
Fazili A, Jazayeri S, Guske C, Durant A, Prunty M, Bukavina L, Lerner S, Tyson M, Gilbert S, Sexton W, Zemp L, Poch M, Rose K, Li R. IP24-34 CISPLATIN INELIGIBLE PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER DEMONSTRATE POOR LONG-TERM SURVIVAL FOLLOWING IMMEDIATE RADICAL CYSTECTOMY: A MULTI-INSTITUTIONAL ANALYSIS. Journal Of Urology 2025, 213: e1278. DOI: 10.1097/01.ju.0001110168.15704.a3.34.Peer-Reviewed Original Research